Ascendis Pharma A/S (NASDAQ:ASND) Given “Overweight” Rating at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a report issued on Tuesday,Benzinga reports. They currently have a $170.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 43.01% from the company’s previous close.

A number of other brokerages have also recently weighed in on ASND. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. TD Cowen dropped their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Stifel Nicolaus raised their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research note on Friday, November 15th. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Finally, Wedbush reiterated an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $191.57.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded down $0.62 during midday trading on Tuesday, hitting $118.88. The company’s stock had a trading volume of 47,049 shares, compared to its average volume of 422,381. The firm has a market cap of $7.21 billion, a P/E ratio of -14.72 and a beta of 0.64. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $161.00. The firm’s fifty day moving average price is $132.32 and its 200-day moving average price is $132.36.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of large investors have recently made changes to their positions in ASND. Loomis Sayles & Co. L P grew its position in Ascendis Pharma A/S by 35.3% during the third quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock valued at $27,566,000 after purchasing an additional 48,120 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Ascendis Pharma A/S by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock valued at $1,664,000 after acquiring an additional 4,338 shares in the last quarter. Valence8 US LP purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at $685,000. Nomura Asset Management Co. Ltd. increased its stake in shares of Ascendis Pharma A/S by 42.5% in the third quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock worth $2,688,000 after acquiring an additional 5,371 shares during the last quarter. Finally, Maven Securities LTD acquired a new stake in Ascendis Pharma A/S during the third quarter valued at $7,466,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.